| Identification | Back Directory | [Name]
1-UFT protocol | [CAS]
74578-38-4 | [Synonyms]
UFT
Ufur
UFT-E
Uftoral
Youfuding
BMS-200604
1-UFT protocol
Tegafur uracil
Tegafur/Uracil
Tegafur·uracil
Tegafur-Uracil
Tegafur-uracil Mixt.
Uracil-Futraful Mixt.
5-fluoro-1-(oxolan-2-yl)pyrimidine-2,4-dione:1H-pyrimidine-2,4-dione | [Molecular Formula]
C12H13FN4O5 | [MDL Number]
MFCD01750796 | [MOL File]
74578-38-4.mol | [Molecular Weight]
312.254 |
| Hazard Information | Back Directory | [Uses]
Tegafur-Uracil (UFT; BMS-200604) is an effective oral chemotherapy drug based on fluoropyrimidine. Tegafur-Uracil inhibits thymidylate synthase. Tegafur-Uracil can be used in combination with leucovorin (LV) and polysaccharide K (PSK) for research on solid tumors[1][2]. | [in vivo]
Tegafur-Uracil (60 mg/kg, orally, once a day for 9 days) combined with folinic acid and protein-bound polysaccharides enhances the anti-tumor activity in mice[2]. | Animal Model: | BLAB/c mice[2] | | Dosage: | 60 mg/kg; daily; 9 days | | Administration: | Oral | | Result: | Reduced tumor size. |
| [References]
[1] Casado E, et al. UFT (tegafur-uracil) in rectal cancer. Ann Oncol. 2008;19(8):1371-1378. DOI:10.1093/annonc/mdn067
[2] Ryoji Katoh, et al. Enhancement of antitumor effect of tegafur/uracil (UFT) plus leucovorin by combined treatment with protein-bound polysaccharide, PSK, in mouse models. Cell Mol Immunol. 2007 Aug;4(4):295-9. PMID:17764620 |
|
| Company Name: |
SPIRO PHARMA
|
| Tel: |
|
| Website: |
www.spiropharma.com.cn |
|